ClinicalTrials.gg
CompletedNCT04994106Updated Oct 5, 2022

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD5462 Following Single and Multiple Ascending Dose Administration to Healthy Volunteers

A Phase 1 interventional study of AZD5462 and Placebo in Healthy Participants, sponsored by AstraZeneca. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-10-05.

Sponsored by AstraZeneca · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Sep 2022, 4 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
98
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

This study will assess the safety, tolerability, and pharmacokinetic (PK) of AZD5462 following single ascending dose (SAD) and multiple ascending dose (MAD) administration in healthy male and female participants and healthy participants of Japanese descent.

Read the detailed description

This Phase I, First in Human (FIH), randomized single-blind, placebo-controlled study will consist of 2 parts (Part A and Part B) with an interleaved study design.

Part A of the study will be a sequential SAD design with 5 dose levels planned to be investigated across 8 cohorts, of which 3 cohorts will solely comprise of participants of Japanese descent. Within each cohort, 6 participants will be randomized to receive AZD5462 and 2 participants randomized to receive placebo.

Part B of the study will be a sequential MAD design with 4 dose levels of AZD5462 planned to be investigated across 5 cohorts, of which 1 cohort will comprise solely of participants of Japanese descent. Within each cohort 6 participants will be randomized to receive AZD5462 and 2 participants randomized to receive placebo.

The duration for participants randomized to Part A of the study is 5 to 6 weeks, and for Part B, 6 to 7 weeks.

02

Conditions studied

  • Healthy Participants

Keywords

  • Healthy participants of Japanese descent
  • First-in-Human
  • 2-part study
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and female (of non-) participants aged 18 to 50 years of age and healthy participants of Japanese descent, 20 to 50 years of age, with suitable veins for cannulation or repeated venipuncture
  • Females must have a negative pregnancy test at the Screening Visit
  • Have a between 18 and 32 kg/m\^2 inclusive and weigh at least 50 kg and no more than 105 kg inclusive
  • For cohorts comprised solely of participants of Japanese descent, a participant will be considered of Japanese descent only if both parents and all grandparents are Japanese

Exclusion criteria

Exclusion Criteria:

  • History of any disease or disorder
  • History or presence of gastrointestinal, hepatic or renal disease or any other condition known to interfere with absorption, distribution, metabolism or excretion of drugs
  • Any clinically important illness, medical/surgical procedure or trauma within 4 weeks of the first administration of study drug
  • Any clinically important abnormalities in clinical chemistry, hematology or urinalysis results
  • Any positive result on Screening for serum surface antigen, antibody, and
  • Abnormal vital signs
  • Any clinically important abnormalities in rhythm, conduction or morphology of the resting (ECG) and any clinically important abnormalities in the 12 lead ECG
  • History of severe allergy/ or ongoing clinically important allergy/hypersensitivity, or history of hypersensitivity to drugs with a similar chemical structure or class to AZD5462
  • Use of any prescribed or nonprescribed medication including antacids, analgesics (other than paracetamol/acetaminophen), herbal remedies, mega dose vitamins (intake of 20 to 600 times the recommended daily dose) and minerals during the 2 weeks or 5 half-lives of the medication, whichever is longer, prior to the first administration of study drug
  • Has received another new chemical entity (defined as a compound which has not been approved for marketing) within 30 days (or 5 half-lives, whichever is the longest) of the first administration of study drug in this study
  • Clinical signs and symptoms consistent with Coronavirus disease 2019, eg, fever, dry cough, dyspnea, sore throat, fatigue, or confirmed infection by appropriate laboratory test within the last 4 weeks prior to Screening or on admission
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
98 participants (actual)

Study arms

  • Experimental
    Cohort A1: AZD5462 Dose 1

    Randomized healthy participants will receive Dose 1 of AZD5462.

    Drug: AZD5462

  • Experimental
    Cohort A2: AZD5462 Dose 2

    Randomized healthy participants will receive Dose 2 of AZD5462.

    Drug: AZD5462

  • Experimental
    Cohort A3: AZD5462 Dose 3

    Randomized healthy participants will receive Dose 3 of AZD5462.

    Drug: AZD5462

  • Experimental
    Cohort A4 Japanese descent: AZD5462 Dose 3

    Randomized participants of Japanese descent will receive Dose 3 of AZD5462.

    Drug: AZD5462

  • Experimental
    Cohort A5: AZD5462 Dose 4

    Randomized healthy participants will receive Dose 4 of AZD5462.

    Drug: AZD5462

  • Experimental
    Cohort A6 Japanese descent: AZD5462 Dose 4

    Randomized participants of Japanese descent will receive Dose 4 of AZD5462.

    Drug: AZD5462

  • Experimental
    Cohort A7: AZD5462 Dose 5

    Randomized healthy participants will receive Dose 5 of AZD5462.

    Drug: AZD5462

  • Experimental
    Cohort A8 Japanese descent: AZD5462 Dose 5

    Randomized participants of Japanese descent will receive Dose 5 of AZD5462.

    Drug: AZD5462

  • Placebo comparator
    Part A: Placebo (Healthy Participants)

    Randomized healthy participants will receive Placebo matched to AZD5462.

    Drug: Placebo

  • Placebo comparator
    Part A: Placebo (Japanese descent participants)

    Randomized participants of Japanese descent will receive Placebo matched to AZD5462.

    Drug: Placebo

  • Experimental
    Cohort B1: AZD5462 Dose 1

    Randomized healthy participants will receive Dose 1 of AZD5462.

    Drug: AZD5462

  • Experimental
    Cohort B2: AZD5462 Dose 2

    Randomized healthy participants will receive Dose 2 of AZD5462.

    Drug: AZD5462

  • Experimental
    Cohort B3: AZD5462 Dose 3

    Randomized healthy participants will receive Dose 3 of AZD5462.

    Drug: AZD5462

  • Experimental
    Cohort B4: AZD5462 Dose 4

    Randomized healthy participants will receive Dose 4 of AZD5462.

    Drug: AZD5462

  • Experimental
    Cohort B5 Japanese descent: AZD5462 Dose 4

    Randomized participants of Japanese descent will receive Dose 4 of AZD5462.

    Drug: AZD5462

  • Placebo comparator
    Part B: Placebo (Healthy participants)

    Randomized healthy participants will receive Placebo matched to AZD5462.

    Drug: Placebo

  • Placebo comparator
    Part B: Placebo (Japanese descent participants)

    Randomized participants of Japanese descent will receive Placebo matched to AZD5462.

    Drug: Placebo

Interventions

  • Participants will receive AZD5462, at dose levels of 1 to 5 in part A and at 1 to 4 in part B, respectively.

  • DrugPlacebo

    Participants will receive Placebo matched to AZD5462.

06

What researchers measure

Primary outcomes

  1. Number of Participants with Adverse Events

    Assessment of the safety and tolerability of AZD5462 following administration of single ascending doses (Part A) and multiple ascending doses (Part B).

    Time frame: Upto Follow-up (Part A: Day 10 ± 3; Part B: Day 19 ± 3)

Secondary outcomes

  1. Maximum observed plasma (peak) drug concentration (Cmax) for AZD5462

    Characterization of the single dose and steady state PK of AZD5462 following administration.

    Time frame: Part A: Day 1 (pre-dose and post-dose), and Days 2, 3, and 10 (post-dose); Part B: Days 1 to 19 (pre and post-doses)

  2. Area under the plasma concentration curve from zero to the last quantifiable concentration (AUClast) for AZD5462

    Characterization of the single dose and steady state PK of AZD5462 following administration.

    Time frame: Part A: Day 1 (pre-dose and post-dose), and Days 2, 3, and 10 (post-dose); Part B: Days 1 to 19 (pre and post-doses)

  3. Area under plasma concentration time curve from zero to infinity (AUCinf) for AZD5462

    Characterization of the single dose and steady state PK of AZD5462 following administration.

    Time frame: Part A: Day 1 (pre-dose and post-dose), and Days 2, 3, and 10 (post-dose); Part B: Days 1 to 19 (pre and post-doses)

  4. Renal clearance of drug from plasma (CLR) for AZD5462

    Characterization of the single dose and steady state PK of AZD5462 following administration.

    Time frame: Part A: Day 1 (pre-dose and post-dose), and Days 2, 3, and 10 (post-dose); Part B: Days 1 to 19 (pre and post-doses)

07

Study locations

1 site
  • Research Site
    Glendale, California 91206, United States
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com /ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at: https://astrazenecagrouptrials.pharmacm.com /ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patientlevel data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at: https://astrazenecagrouptrials.pharmacm.com /ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2021 to primary completion in Sep 2022, 13 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2021
First posted
Aug 6, 2021
StartActual
Jul 27, 2021
Primary completionActual
Sep 20, 2022
CompletionActual
Sep 20, 2022
Last update
Oct 5, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 5, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04994106
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Aug 6, 2021
Start date
Jul 27, 2021
Primary completion
Sep 20, 2022
Completion
Sep 20, 2022
Last update
Oct 5, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pexerelgon

Start the discussion